Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06161571
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2023-11-22
Brief Title:
A Study Evaluating Efruxifermin in Subjects with Non-invasively Diagnosed Nonalcoholic Steatohepatitis NASHMetabolic Dysfunction-Associated Steatohepatitis MASH and Nonalcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatotic Liver Disease MASLD
Sponsor:
Akero Therapeutics Inc
Organization:
Akero Therapeutics Inc
Study Overview
Official Title:
A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-invasively Diagnosed Nonalcoholic Steatohepatitis NASHMetabolic Dysfunction-Associated Steatohepatitis MASH and Nonalcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatotic Liver Disease MASLD
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASHMASH and NAFLDMASLD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None